The New England Journal of Medicine publishes these papers, some free, some on subscription, and the abstracts are tantalising sometimes.
I'm not going to pay for it 'cos I'm a stingy Scot and a T1. Mind you, even if I was a T2 with money to burn, I don't know if I'd be rushing to spend it on reading such dire predictions. If anyone has deep pockets and it turns out to be a low-carb recruiting tool, please let me know!
All the best,
fergus
Optimal Insulin Treatment in Type 2 Diabetes
Michael Roden, M.D.
Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.
Patients with type 2 diabetes have peripheral insulin resistance and inadequate insulin secretion by pancreatic beta cells. During meals, reduced first-phase insulin secretion results in postprandial hyperglycemia and in a 35% decrease in hepatic glycogen storage.1 A 55% increase in nocturnal hepatic gluconeogenesis drives excessive glucose production and fasting hyperglycemia.1 Ultimately, in 90% of patients with progressive beta-cell insufficiency, lifestyle changes and oral drug therapy are insufficient, and patients require exogenous insulin supplementation to achieve a glycated hemoglobin level below the recommended 7% target.
I'm not going to pay for it 'cos I'm a stingy Scot and a T1. Mind you, even if I was a T2 with money to burn, I don't know if I'd be rushing to spend it on reading such dire predictions. If anyone has deep pockets and it turns out to be a low-carb recruiting tool, please let me know!
All the best,
fergus